PL388403A1 - Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej - Google Patents

Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej

Info

Publication number
PL388403A1
PL388403A1 PL388403A PL38840309A PL388403A1 PL 388403 A1 PL388403 A1 PL 388403A1 PL 388403 A PL388403 A PL 388403A PL 38840309 A PL38840309 A PL 38840309A PL 388403 A1 PL388403 A1 PL 388403A1
Authority
PL
Poland
Prior art keywords
virus
proteins
particle
vector particle
pharmaceutical composition
Prior art date
Application number
PL388403A
Other languages
English (en)
Other versions
PL222497B1 (pl
Inventor
Jadwiga Chroboczek
Ewa SZOŁAJSKA
Antonina Naskalska
Original Assignee
Instytut Biochemii I Biofizyki Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Pan filed Critical Instytut Biochemii I Biofizyki Pan
Priority to PL388403A priority Critical patent/PL222497B1/pl
Priority to PCT/PL2010/000051 priority patent/WO2010151159A2/en
Priority to EP10737125.4A priority patent/EP2461827B1/en
Publication of PL388403A1 publication Critical patent/PL388403A1/pl
Publication of PL222497B1 publication Critical patent/PL222497B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem wynalazku jest wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, zastosowanie oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną. Bardziej szczegółowo rozwiązanie dotyczy białkowej wektorowej cząsteczki wirusopodobnej, stanowiącej dodekahedron adenowirusowy (Dd), dostarczającej do tkanek ssaczych substancje terapeutyczne, pochodzące z klasy białek, peptydów, polisacharydów, kwasów nukleinowych, tłuszczów, lipoprotein lub ich pochodnych. Przedmiotowe rozwiązanie umożliwia uzyskanie szczepionek ludzkich lub zwierzęcych, dostarczenie do tkanek ssaczych przeciwciał, substancji antynowotworowych, kwasów nukleinowych, enzymów oraz substancji immunosupresyjnych, a także białek/peptydów i lipidów specyfikujących tropizm tkankowy. W sposobie według wynalazku domeny WW pochodzą z białka grzybów, zwłaszcza białka szczepów drożdżowych.
PL388403A 2009-06-26 2009-06-26 Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej PL222497B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL388403A PL222497B1 (pl) 2009-06-26 2009-06-26 Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
PCT/PL2010/000051 WO2010151159A2 (en) 2009-06-26 2010-06-24 Virus-like particle vector as a polyvalent platform for intracellular delivery of high-molecular-weight therapeutic substances, method for generating a virus like particle vector and use of a virus-like particle vector and a pharmaceutical composition containing said virus-like particle vector
EP10737125.4A EP2461827B1 (en) 2009-06-26 2010-06-24 Virus-like particle vector as a polyvalent platform for intracellular delivery of high-molecular-weight therapeutic substances, method for generating a virus like particle vector and use of a virus-like particle vector and a pharmaceutical composition containing said virus-like particle vector

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL388403A PL222497B1 (pl) 2009-06-26 2009-06-26 Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej

Publications (2)

Publication Number Publication Date
PL388403A1 true PL388403A1 (pl) 2011-01-03
PL222497B1 PL222497B1 (pl) 2016-08-31

Family

ID=42829079

Family Applications (1)

Application Number Title Priority Date Filing Date
PL388403A PL222497B1 (pl) 2009-06-26 2009-06-26 Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej

Country Status (3)

Country Link
EP (1) EP2461827B1 (pl)
PL (1) PL222497B1 (pl)
WO (1) WO2010151159A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE072880T2 (hu) 2016-03-31 2025-12-28 The European Molecular Biology Laboratory Adenovírus szálfehérjékbõl származó módosított polipeptidek és a polipeptideket tartalmazó VLP-k
CN106755106A (zh) * 2017-01-06 2017-05-31 华中农业大学 安卡拉病毒亚单位疫苗的制备方法及应用
MX2022009574A (es) * 2020-02-05 2022-11-16 Imophoron Ltd Polipéptidos modificados derivados de dominio variable de la base pentona de adenovirus.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2747681B1 (fr) 1996-04-18 1998-06-19 Commissariat Energie Atomique Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications
JP2000500020A (ja) 1995-11-13 2000-01-11 コミサリア・ア・レネルジー・アトミーク 正十二面体様アデノウイルス・タンパク質複合体、それを含む組成物、及びその使用方法
FR2741087B1 (fr) 1995-11-13 1998-01-09 Commissariat Energie Atomique Complexe proteique dodecaedrique adenoviral, procede de preparation, composition le contenant et ses applications
PL192016B1 (pl) 1998-11-30 2006-08-31 Cytos Biotechnology Ag Kompozycja, sposób wytwarzania sztucznego, uporządkowanego i powtarzalnego układu antygenu, zastosowanie kompozycji oraz kompozycja szczepionki
US20010036463A1 (en) 2000-03-09 2001-11-01 Compans Richard W. Transcutaneous immunization for large particulate antigens
DK1294892T3 (da) * 2000-06-23 2008-01-28 Wyeth Corp Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)
EP1862550A1 (en) 2000-06-23 2007-12-05 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
ES2385842T3 (es) 2005-12-06 2012-08-01 Yeda Research And Development Co., Ltd. Vacuna mejorada contra la gripe
BR122019013216B8 (pt) 2006-01-27 2021-07-27 Seqirus Uk Ltd ensaio imunológico para análise de uma vacina contra influenza
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
JP2010533737A (ja) 2007-07-19 2010-10-28 ノババックス，インコーポレイテッド キメラ水痘帯状疱疹ウイルス−ウイルス様粒子

Also Published As

Publication number Publication date
WO2010151159A3 (en) 2011-04-07
WO2010151159A2 (en) 2010-12-29
PL222497B1 (pl) 2016-08-31
EP2461827B1 (en) 2016-08-10
EP2461827A2 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
Wang et al. Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity
Jesus et al. Exosomes as adjuvants for the recombinant hepatitis B antigen: First report
CN120035678A (zh) 用于调节循环因子的组合物和方法
Liu et al. Nanoparticles-based multi-adjuvant whole cell tumor vaccine for cancer immunotherapy
Blom et al. A triple co-culture model of the human respiratory tract to study immune-modulatory effects of liposomes and virosomes
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
EP4036079A3 (en) Compounds and compositions for intracellular delivery of agents
MX2019011004A (es) Compuestos y composiciones para la administracion intracelular de agentes terapeuticos.
RU2013104171A (ru) Микровезикулы, происходящие из протопластов клеток, и их применение
Kar et al. Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
MA46647A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MX342608B (es) Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
EA201891874A2 (ru) Новые пептиды, комбинации пептидов и каркасы для применения в иммунотерапевтическом методе лечения различных видов рака
PH12013501926A1 (en) Nutritional compositions having alpha-hica and citrulline
EA201792044A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
EA201790989A1 (ru) Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации
NZ716192A (en) Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
CN104225572A (zh) 脑蛋白水解物及其制备方法
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
WO2010151159A3 (en) Virus-like particle vector as a polyvalent platform for intracellular delivery of high-molecular-weight therapeutic substances, method for generating a virus like particle vector and use of a virus-like particle vector and a pharmaceutical composition containing said virus-like particle vector
Zhang et al. Pulmonary delivery of small circular RNA vaccines for influenza prevention
Zhu et al. Inverted HA-EV immunization elicits stalk-specific influenza immunity and cross-protection in mice
WO2015157611A3 (en) Improvements to eukaryotic transposase mutants and transposon end compositions for modifying nucleic acids and methods for production and use in the generation of sequencing libraries